Trending NewsTrending NewsNASDAQ:BIIB Biogen (BIIB) Stock Price, News & Analysis $220.54 -2.29 (-1.03%) As of 02:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Biogen Stock (NASDAQ:BIIB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biogen alerts:Sign Up Key Stats Today's Range$220.17▼$224.0850-Day Range$200.14▼$228.6952-Week Range$138.00▼$230.49Volume396,732 shsAverage Volume1.20 million shsMarket Capitalization$32.58 billionP/E Ratio39.03Dividend YieldN/APrice Target$230.14Consensus RatingModerate Buy Company Overview Biogen Inc. is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders. Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia. The company also partnered with Eisai on Leqembi (lecanemab), an Alzheimer’s disease treatment, and has participated in the development and commercialization of biosimilars through its collaboration with Samsung Bioepis. Founded in 1978, Biogen is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world. The company’s operations include research and development, regulatory support, manufacturing and commercial activities across North America, Europe and other international regions. Biogen is led by Chief Executive Officer Christopher A. Viehbacher.AI Generated. May Contain Errors. Read More Biogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreBIIB MarketRank™: Biogen scored higher than 56% of companies evaluated by MarketBeat, and ranked 508th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingModerate Buy Consensus RatingBiogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 17 buy ratings, 13 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Biogen is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBiogen has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biogen's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth29.81% Earnings GrowthEarnings for Biogen are expected to grow by 29.81% in the coming year, from $12.41 to $16.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biogen is 39.06, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Biogen is 39.06, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.21.Price to Earnings Growth RatioBiogen has a PEG Ratio of 2.49. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBiogen has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biogen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.95% of the float of Biogen has been sold short.Short Interest Ratio / Days to CoverBiogen has a short interest ratio ("days to cover") of 7.59.Change versus previous monthShort interest in Biogen has recently increased by 1.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiogen does not currently pay a dividend.Dividend GrowthBiogen does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.02 News SentimentBiogen has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Biogen this week, compared to 11 articles on an average week.Search Interest19 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biogen insiders have not sold or bought any company stock.Percentage Held by Insiders0.25% of the stock of Biogen is held by insiders.Percentage Held by Institutions87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biogen's insider trading history. Receive BIIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIIB Stock News HeadlinesBiogen's experimental lupus drug shows benefit against skin symptoms26 minutes ago | msn.comBiogen Reports 52-Week Litifilimab Data In Cutaneous Lupus; Phase 3 Readout Ahead26 minutes ago | rttnews.comThe rich already moved their moneyBy the time a crash hits the news, it's already too late to protect your money. Parkview Capital's free Market Crash Survival Guide breaks down the specific warning signs flashing in the economy right now the same signals that preceded 2008, 2000, and other downturns that caught unprepared investors off guard. You don't need a financial advisor just ten minutes to see what the data is showing.October 2 at 1:00 AM | Parkview Capital Group (Ad)Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class ...26 minutes ago | markets.businessinsider.comBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus26 minutes ago | finance.yahoo.comBiogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook1 hour ago | tipranks.comBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus2 hours ago | financialpost.comFBiogen Reports 52-Week Phase 2 AMETHYST Data Showing Durable and Rapid Litifilimab Response in Cutaneous Lupus Erythematosus2 hours ago | quiverquant.comQSee More Headlines BIIB Stock Analysis - Frequently Asked Questions How have BIIB shares performed this year? Biogen's stock was trading at $175.99 at the beginning of 2026. Since then, BIIB stock has increased by 25.4% and is now trading at $220.71. How were Biogen's earnings last quarter? Biogen Inc. (NASDAQ:BIIB) released its earnings results on Wednesday, July, 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.94 by $0.66. The company's revenue was up 3.4% compared to the same quarter last year. Read the conference call transcript. Does Biogen have any subsidiaries? Biogen subsidiaries include these companies: Nightstar Therapeutics plc, Convergence Pharmaceuticals, TYSABRI, Stromedix Inc., Panima Pharmaceuticals AG, Syntonix Pharmaceuticals Inc., Fumapharm, and more. How do I buy shares of Biogen? Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biogen investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Intel (INTC). Company Calendar Last Earnings7/29/2026Today10/02/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BIIB's financial health is in the Green zone, according to TradeSmith. BIIB has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BIIB CIK875045 Webwww.biogen.com Phone(617) 679-2000Fax617-679-2617Employees7,500Year Founded1978Price Target and Rating Average Price Target for Biogen$230.14 High Price Target$300.00 Low Price Target$175.00 Potential Upside/Downside+4.3%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage32 Analysts Profitability EPS (Trailing Twelve Months)$5.65 Trailing P/E Ratio39.07 Forward P/E Ratio17.78 P/E Growth2.49Net Income$1.29 billion Net Margins8.32% Pretax Margin10.09% Return on Equity11.18% Return on Assets6.88% Debt Debt-to-Equity Ratio0.39 Current Ratio1.87 Quick Ratio1.26 Sales & Book Value Annual Sales$9.89 billion Price / Sales3.30 Cash Flow$22.11 per share Price / Cash Flow9.98 Book Value$124.45 per share Price / Book1.77Miscellaneous Outstanding Shares147,750,000Free Float147,385,000Market Cap$32.60 billion OptionableOptionable Beta0.09 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BIIB) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe last few crashes started exactly like thisEvery major market crash shared one thing in common: most investors felt confident right before it hit. Ove...Parkview Capital Group | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
